Background. Sanofi Pasteur has developed a tetravalent dengue vaccine (TDV) against the world's most common arbovirus infection.
and its range is expanding [1] [2] [3] [4] [5] . Dengue virus can cause a continuum of disease: dengue fever causes biphasic fever, rash, extreme muscle or joint pain, headache, and eye pain; dengue hemorrhagic fever causes abnormal homeostasis and increased vascular permeability, with severe cases leading to dengue shock syndrome. Exposure generates life-long, serotype-specific immunity, but subsequent infections with other serotypes may increase the risk of severe disease. Complex disease presentation and sudden development of hemorrhagic symptoms in seemingly stable patients can cause fatal outcomes even in well-prepared hospitals [2] [3] [4] .
No vaccine or treatment exists; mosquito control and personal protection are the primary defenses. The scale of the problem and the cost of protective measures make vaccine development a public health priority [1] [2] [3] [4] [5] [6] . Previous live attenuated vaccines developed through serial cell-culture passages were under-or overattenuated or caused cross-strain interference [1, [6] [7] [8] [9] [10] [11] [12] [13] [14] . We evaluated a tetravalent dengue vaccine (TDV) that was developed using recombinant technology and that contained genes from the attenuated 17D yellow fever (YF 17D) vaccine virus and genes for premembrane (prM) and envelope (E) proteins of each dengue serotype. The resulting dengue vaccine strains possess the antigencity of the parental virus in combination with the well-characterized YF 17D replication engine [7, 8, 15] . A live attenuated tetravalent vaccine is formulated with 4 recombinant dengue viruses. Early clinical trials of monovalent and tetravalent candidates containing ∼4 log 10 median tissue culture infective doses (TCID 50 ) of dengue vaccine strains showed promise [7, 8] . We evaluated the immunogenicity and safety of a formulation with ∼5 log 10 TCID 50 of each recombinant dengue serotype in Flavivirus-naive adults.
METHODS
We performed a phase 1 clinical trial at Bio-Kinetic Clinical Applications (Springfield, Missouri) to describe the safety profile and immunogenicity of TDV in 18-45-year-olds, following the Declaration of Helsinki principles; an institutional review board approved the study.
Participants. Healthy men and women aged 18-45 years who provided written informed consent were eligible. Women were neither pregnant nor breast-feeding, and they used effective birth control from у4 weeks before screening until 4 weeks after the final vaccination. Persons with a history of thymic disease, thymectomy, myasthenia gravis, immunodeficiency, long-term systemic corticosteroid therapy, systemic hypersensitivity to any study injection or component, Flavivirus infection or vaccination (including planned vaccination), or 12 weeks' residence in an area of high dengue endemicity (including planned travel) were excluded. Those with comorbid conditions that could interfere with participation or confound results, those with predefined laboratory abnormalities at screening, and those who were seropositive for human immunodeficiency virus or hepatitis B or C virus were also ineligible.
Vaccine. Sanofi Pasteur's TDV was developed with Acambis (now a part of Sanofi Pasteur) based on ChimeriVax (CV) technology. The liquid formulation is composed of 4 bulk monovalent vaccines produced by a phase 1 manufacturing process, CV-DEN-1-4. Monovalent, live attenuated CV-DEN vaccines are produced by replacing the prM and E genes of the YF 17D vaccine infectious clone with the corresponding dengue virus genes [15] . The vaccine was stored frozen at below Ϫ60ЊC. Each 0.5-mL dose, containing ∼5 log 10 TCID 50 of each recombinant dengue virus serotype, was administered subcutaneously to the right deltoid, as was the saline placebo (sodium chloride). Actual log 10 TCID 50 values for serotypes 1, 2, 3, and 4 were 4.3, 4.8, 4.6, and 4.5. TDV is formulated in minimum essential medium containing human serum albumin (2.5%; United States Pharmacopeia) and lactose (7.5%). All vaccines were manufactured and supplied by Sanofi Pasteur. The TCID 50 assay is a limit dilution assay with statistical titer calculation. Log 10 titers are obtained directly, whereas plaque-forming units (PFUs) are expressed as an inverse of dilution converted to geometric values. The theoretical difference between PFUs and TCID 50 is 0.16 log 10. However, it is never detected because of the variability of biological assays (standard deviation [SD], ‫2.0ע‬ to ‫3.0ע‬ log 10 ).
Vaccination schedule. Participants were randomized into 2 groups (Figure 1) , with blocking for even distribution. Both groups received 3 subcutaneous injections: the first injection was given on day 0, the second injection was given on 4 months after the first injection, and the third injection was given 12-15 months after the first injection. Group 1 received TDV at each injection. Group 2 received saline placebo as a first injection and TDV as second and third injections. First injections were performed in a double-blind fashion; subsequent injections were performed in an open-label fashion. To maintain blinding, the personnel preparing and administering the vaccines were different from those evaluating the participants. Vaccinations were staggered: a first cohort of 18 participants was followed to day 14, when an independent data monitoring committee evaluated the safety profile and recommended proceeding with enrollment. Participants completed 31 trial visits, with blood samples obtained at each visit.
Safety assessments. A physical examination was performed at screening visits, on vaccination days, and 28 days after each vaccination. A physical examination was also performed during interim visits if necessary, on the basis of health status or the reporting of adverse events. Oral temperature was recorded at each visit. Study personnel assessed safety for 30 min after each vaccination. Participants recorded solicited injection site reactions of pain, erythema, and swelling for 7 days and systemic reactions of fever, headache, malaise, myalgia, and asthenia on study-provided diary cards for 14 days after each injection. Injection site pain was classified as mild (easily tolerated), moderate (interferes with normal activities), or severe (incapacitating). Injection site erythema and swelling were classified as mild (!2.5 cm), moderate (у2.5 to !5 cm), or severe (у5 cm). Fever was classified as mild (у37.5ЊC to 38.0ЊC), moderate (у38.1ЊC to 39.0ЊC), or severe (у39.1ЊC) on the basis of oral temperature. Other systemic adverse events were classified as mild (noticeable but does not interfere with activities), moderate (interferes with activities), or severe (prevents daily activities). Spontaneously reported adverse events occurring up to 28 days after each injection were also recorded. Serious adverse events were recorded throughout the study. At each visit, the investigator queried participants regarding any solicited reactions and unsolicited adverse events recorded on the diary card (as well as any other adverse events) and performed a clinical examination when necessary.
Samples for baseline complete blood counts and blood chemistry analysis were collected on day 0. Samples collected 4, 8, 12, 16 , and 28 days after the first and second injections and 8 and 28 days after the third injection were evaluated for biochemistry, hematology, and coagulation parameters. Biological tests and solicited reactions were categorized using a predefined severity scale. The investigator assessed adverse event severity and determined their relationship to study injections on the basis of clinical findings.
Viremia. Viremia for the 4 dengue virus serotypes was evaluated in serum samples collected every 48 h for 20 days after the first and second injections and on days 8 and 16 after the third injection. Serum samples were first tested at Sanofi Pasteur (Swiftwater, Pennsylvania) for non-serotype-specific TDV viremia by reverse-transcription polymerase chain reaction (RT-PCR) with primers from a yellow fever-specific core gene sequence targeting the yellow fever genes common to all vaccine serotypes. Results were quantified by a nucleic acid-based assay and expressed as a concentration of log 10 PFU equivalents per milliliter (lowest level of quantification [LLOQ], 1.46 log 10 PFU/ mL). Positive samples were tested by serotype-specific quantitative RT-PCR [16] , and quantitative tissue culture was tested by plaque assay [17] . RT-PCR results were expressed as a concentration in log 10 genome equivalents (GEQs) per milliliter (LLOQs were 4.83, 4.74, 4.97, and 4.99 log 10 GEQ/mL for DENV-1-4, respectively). Virus titer in the plaque assay was expressed as log 10 PFU/mL (LLOQ, 1.6 log 10 PFU/mL).
Immunogenicity. The humoral immune response was assessed via levels of neutralizing antibodies against the 4 dengue virus serotypes (World Health Organization [WHO] reference strains: DENV-1, West Pac 74; DENV-2, S16803; DENV-3, CH53489; DENV-4, 341750 [TVP-360]) at Mahidol University (Bangkok, Thailand) in serum samples collected before the first injection and 28 days after the first, second, and third injection, using a plaque reduction neutralization test (PRNT) on LLC-MK2 cells [18] , in accordance with WHO guidelines [19] . Geometric mean titers (GMTs) were expressed as the reciprocal of dilution, with values у10 considered to be seroconverted for the corresponding serotype (LLOQ, 5 [the lowest PRNT serum dilution]).
RESULTS

Participants
Sixty-six participants were enrolled, randomized, and underwent study procedures between October 2005 and February 2007. Groups had similar demographic characteristics (Table  1) . Three participants in group 1 withdrew between the first and second injections (one was disqualified by the investigator after aggravated depression, and the others withdrew voluntarily). Seven from each group withdrew between the second and third injections (Figure 1 ). Tables 2 and 3 summarize adverse events and specific adverse events for 28 days after each injection. There were 5 serious adverse events during the study, all in group 1. None were The most frequent solicited systemic reactions were headache, malaise, myalgia, asthenia, and fever. Few injection site reactions were recorded. Pain was the most frequent reaction after all 3 injections. In total, 57.5% of participants in group 1 and 36.3% in group 2 reported unsolicited adverse events after the first TDV administration (the first injection for group 1 and the second injection for group 2). Most reactions were mild, self-limiting, and resolved within 3 days of onset.
Safety Parameters
First TDV injection. After the first vaccination, a higher but not statistically significant proportion of participants in group 1 experienced an adverse reaction, primarily a higher incidence of systemic reactions. Asthenia, myalgia, and injection site pain tended to occur more frequently with TDV. Two participants in group 1 reported severe malaise; 1 had severe myalgia, and 1 had both severe malaise and myalgia. One episode of rash was seen in group 2 after the first injection.
One participant in group 1 had a severe increase (у4.0 times the upper limit of normal) in creatine phosphokinase (CPK) level (1139 U/L) 28 days after vaccination. Two participants in group 2 reported severe pyrexia (oral temperature, у39.1ЊC) after the first TDV injection. The pyrexia occurred on the day of vaccination and remained for 3 days for one participant and 1 day for the other participant. The maximum temperature was 39.9ЊC. One of the two subjects also experienced injection site pain the day of vaccination; otherwise, neither participant presented any other symptom or biological abnormality. One presented with a severe increase in CPK level (9336 U/L) 8 days after vaccination, and one presented with a severe decrease (! cells /L) in neutrophil count ( cells/L) 8 9 9 1.0 ϫ 10 0.8 ϫ 10 days after vaccination. Two participants also presented with severe but transient increases in CPK levels (8125 and 5676 U/ L) occurring on day 12 after receipt of placebo. All severe values returned to normal within 1 week and were not associated with clinical symptoms. Participants with a severe elevation in CPK levels were questioned about exercise. In all cases they mentioned an intense exercise period concurrent with the elevation in CPK level; in addition, measures of isoenzymes in one subject showed it to be the MM CPK isoenzyme. Few participants presented with abnormal values for biochemical parameters at any time point, with no differences seen between groups.
Two participants in group 2 experienced severe fever (temperature, 139.1ЊC) after the second injection (ie, after the first TDV injection) that lasted for 1 and 3 days. Both episodes were considered to be vaccine related in the analysis. The most common biological abnormality after the first TDV dose was a transient decrease in white blood cell (WBC) count. In participants with normal baseline values, decreases in WBC count were more frequent in group 1 (9 participants) than in group 2 (1 participant). The decreases occurred particularly on day 8 after the first dose, and they were not associated with clinical symptoms. Second and third TDV injections. A second TDV dose did not increase the proportion of participants with at least 1 solicited systemic reaction. One participant reported severe headache, malaise, myalgia, and asthenia. One participant experienced an episode of mild swelling of the face that was not vaccine related 11 days after the second TDV injection in group 1. After the third TDV dose, the proportion of participants with at least 1 solicited reaction decreased. No severe reactions were reported. In group 1, fewer changes were observed after the second and third injections, with 4 participants presenting with a decrease in WBC count.
Viremia
Little viremia was detected, with most values !1.46 log 10 PFU/ mL (the LLOQ for yellow fever RT-PCR). Consequently, viremia results were expressed as the percentage (%) of participants with detectable viremia (ie, greater than or equal to lower limit of detection). The percentage of participants with detectable viremia at any time point was 78.9% after the first TDV dose. Viremia was observed mainly on days 8 and 14. DENV-4 viremia was detected most often, followed by DENV-3. Four participants were positive by plaque assay (maximum value, 1.6 log 10 PFU/mL). Viremia occurred in only 4 partici- pants (13.3%) after a second TDV dose. DENV-2 was detected in 2 samples, but neither were positive by plaque assay. Only one participant had detectable viremia after the third TDV dose (positive plaque assay result for DENV-3), and none had viremia 1LLOQ.
Immunogenicity
The humoral immune response increased correspondingly with the number of TDV doses. Seroconversion rates (percentage of participants with a PRNT titer of у10) for each serotype after each vaccination are shown in Figure 2 , and GMT values are shown in Figure 3 . An increased seroconversion rate was consistently associated with a higher GMT. DENV-1. In group 1, 12.1% of participants seroconverted to DENV-1 (West Pac 74), and the GMT was 3.05 (range, 2.50-21.0) after the first injection. After the second injection, the seroconversion rate was 70.0%, and the GMT was 20.5 (range, 2.50-797). After the third injection, the seroconversion rate was 100% after the third TDV injection, with a GMT of 67.1 (range, 24.0-217). In group 2 after the second injection (ie, the first TDV dose), the DENV-1 seroconversion rate was 30.3%, and the GMT was 5.39 (range, 2.50-167). After the third injection (ie, the second TDV dose), the seroconversion rate was 92.3%, and the GMT was 37.8 (range, 2.50-429). Seroconversion rate and GMT increases between TDV doses were greater when doses were given 8-11 months apart (ie, between the second and third injections in group 2) than when doses were given 4 months apart (between the first and second injections in group 1). DENV-2. In group 1, the DENV-2 (S16803) seroconversion rate increased from 66.7%, to 93.3%, and to 100% after the first, second, and third injections, respectively. GMT increased from 57.2 (range, 2.50-66112) to 343 (range, 2.50-845972) and 538 (range, 30.0-6435). In group 2, the seroconversion rate increased from 72.7% to 100%, and the GMT increased from 57.8 (range, 2.50-14367) to 301 (range, 19.0-6435) after the second and third injections.
DENV-3. In group 1, the DENV-3 (CH53489) seroconversion rate increased 27.3%, to 73.3%, and to 100% after the first, second, and third injections, respectively. The GMT rose from 5.99 (range, 2.50-835), to 19.7 (range, 2.50-431), and to 122 (range, 16.0-947) after the first, second, and third injections, respectively. The group 2 seroconversion rate rose form 33.3% after the second injection to 100% after the third injection. The GMT rose from 6.34 (range, 2.50-434) to 88.4 (range, 13.0-685) after the third injection. Seroconversion rate and GMT increases between the 2 TDV doses were greater when given 8-11 months apart than when given 4 months apart.
DENV-4. In group 1, the DENV-4 (341750 [TVP-360]) seroconversion rate increased from 63.6%, to 86.7%, and to 100% after the first, second, and third injections, respectively. The GMT was 31.0 (range, 2.50-2255), 61.3 (range, 2.50-890), and 154 (range, 35.0-1481) after the first, second, and third injections, respectively. In group 2, the DENV-4 seroconversion rate was 87.9% after the second injection and 100% after the third injection; the GMT was 57.3 (range, 2.50-3639), reaching 107.0 (range, 14.0-571) after the third injection.
DISCUSSION
We evaluated a novel tetravalent dengue vaccine candidate containing vaccine viruses of the 4 dengue virus serotypes attenuated by recombinant technology based on the YF 17D vaccine strain [7, 8, 12, 15] in Flavivirus-naive adults. The vaccine was well tolerated and induced seroconversion against all 4 serotypes in all subjects after 3 doses given at 0, 4, and 12-15 months and in almost all subjects after 2 doses given 8-11 months apart.
No safety signal was detected, and all reported serious adverse events were deemed unrelated to the vaccine. After the first study vaccination, more systemic reactions were observed in group 1 (TDV) than in group 2 (placebo). However, adverse events were variable, and the proportion of systemic reactions in all participants after the first dose of TDV (ie, pooled group 1 first injection and group 2 second injection) was close to placebo recipients. These proportions were stable after the second vaccination and decreased markedly in group 1 after the third TDV injection. The overall safety evaluation of the successive vaccinations showed that a first dose of TDV did not increase the reactogenicity of the subsequent second and third doses. Transient decreases in WBC count were observed more frequently in group 1 than in group 2, occurring mainly 1 week after the first TDV dose at the same time as a peak in viremia. Both episodes of severe fever after the second injection of TDV in group 2 may have been unrelated because they were isolated and appeared very quickly after the injection. The novel TDV attenuated by recombinant technology had an improved safety profile compared with some empirically live attenuated vaccines, which may cause mild dengue-like symptoms, such as rash and fever [10, [12] [13] [14] .
Little viremia was observed, mainly from DENV-4 after the first TDV dose, consistent with the vaccine's good safety profile. After the second TDV injection, no viremia was detected in group 1 by RT-PCR or plaque assay for any serotype except DENV-2 for one participant, 12 and 18 days after vaccination. The absence of DENV-4 viremia may be related to the strong humoral response induced against this serotype after the first TDV administration, which might inhibit its replication. This is consistent with the immune response observed after the sec- ond TDV dose, that is, a limited increase in the response against DENV-4 and a more pronounced increase against the other serotypes. DENV-1, DENV-2, and DENV-3 viremia was absent in 185% of vaccinees after the second vaccination, which showed that the first TDV administration did sensitize participants to a second dose despite incomplete DENV-1, DENV-2, and DENV-3 seroconversion after the first dose and the presence of heterologous anti-DENV-4 antibodies.
All participants receiving 3 TDV doses seroconverted against all 4 WHO reference strains. An increased immune response with an increased number of doses was apparent: both the GMT and seroconversion rate increased with additional vaccine doses. The first TDV dose induced a neutralizing humoral response mainly against DENV-4 and DENV-2, and to a lesser extent against DENV-1 and DENV-3, which agrees with postvaccinal viremia data for DENV-4. The second and third doses increased the seroconversion rate and GMTs for all 4 serotypes, balancing the immune response across all 4 serotypes. Moreover, there was a trend toward higher GMTs and higher seroconversion rates in group 2 than in group 1 after 2 TDV doses (especially for DENV-1 and DENV-3), that is, a longer time between doses (8-10 months between the second and third injections in group 2 compared with 4 months between the first and second vaccinations in group 1). In fact, seroconversion against all 4 serotypes was observed in almost all vaccinees from group 2 after 2 TDV doses 8-11 months apart, as a longer interval would appear to limit viral interferences between doses. The mechanism of short-term interference has not been fully defined, but the phenomenon may be similar to the heterologous, short-lived cross-protection among dengue serotypes first described by Sabin [20] . Possible mediators of such interferences with the second vaccine dose are broadly crossreactive (immunoglobulin M) antibodies generated after the primary immunization. These cross-reactive antibodies can be directed not only against the initially dominant serotype(s) but also against the initially low-responding ones, so they may still be capable of neutralizing them after a booster dose for a limited time. These antibodies disappear after several months, allowing better replication on the nondominant serotypes and a balanced immune response across serotypes. The present data also agree with observations in monkeys immunized with the same TDV, in which a third dose given 10 months after the second induced a dramatic increase in immune responses against all 4 serotypes, which was not seen when the third dose was given only 2 months after the second [21] . Alternatively-or in additiona longer time interval may allow a better maturation of immune memory. Interferences between serotypes as observed in monkeys [21] may also explain why viremia and PRNT levels in this study were lower for DENV-2 after primary immunization, compared with those after monovalent CV-DENV-2 immunization [7] . In addition, owing to the lack of PRNT standardization, any head-to-head comparison of the PRNT values over time or between laboratories is of questionable validity. As previously reported, the level and nature of cellular immune responses (cytokine profile, CD8/T helper bias, and serotype dominance) of innate and adaptive cellular responses agree with the present safety profile and humoral immunogenicity data [22] .
In conclusion, a new candidate dengue vaccine developed with recombinant technology showed an improved safety profile compared with empirically attenuated live virus vaccines [10, [12] [13] [14] and induced immune responses against all serotypes. We examined relatively few Flavivirus-naive participants, and safety and immunogenicity data in more participants (especially children) and studies in Flavivirus-immune populations are still needed. However, this is an important step that supports the recommendations of the UNICEF/UNDP/World Bank/WHO Special Program for Research and Training on Tropical Diseases, which include vaccine development in conjunction with case management, reducing transmission, and enhancing public health response [1] . These results paved the way for ongoing and future large-scale efficacy trials of our candidate and helped optimize the immunization schedule (3 doses, 6 months apart), which limits short-term viral interference and improves vaccine take and complementation of the immune response. Large-scale trials will examine the protection after 2 doses in detail. Furthermore, prior Flavivirus immunity may induce neutralizing immune responses more rapidly, as observed in preclinical studies [21] , and reduce the number of doses while maintaining full protection.
